Aeras, OETC commence TB drug Phase IIb trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Adaptive RCTs: Transforming Clinical Trials for Efficiency

Randomised controlled trials (RCTs) have long been the gold...

Big Data Integration Transforming Clinical Trials

In the years that have gone by, the big...

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

Asia’s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more...

Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) have commenced a Phase IIb trial to investigate a new experimental tuberculosis vaccine in TB patients with human immunodeficiency virus (HIV) infection.

The trial will evaluate the HIV patients who are using MVA85A, which is being developed by OETC, a joint venture between the University of Oxford and Emergent BioSolutions, and Aeras.The trial will test the vaccine candidate in around 1,400 HIV adults of 18-50 ages.Aeras president and CEO Jim Connolly said studies have already shown that this promising vaccine has an acceptable safety profile and stimulates strong immune responses in HIV-infected individuals.

 

Latest stories

Related stories

Adaptive RCTs: Transforming Clinical Trials for Efficiency

Randomised controlled trials (RCTs) have long been the gold...

Big Data Integration Transforming Clinical Trials

In the years that have gone by, the big...

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

Asia’s CROs VCs: Blurring Service Provider & Investor Roles

In a time characterized by accelerated innovation and ever-more...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back